Ischemic Cholangiopathy clinical trials at UCSD

1 in progress, 0 open to eligible people

Single-arm, Investigator-initiated Study (SELIC) to Evaluate the Efficacy and Safety of Seladelpar in Adult Liver Transplant Recipients With Ischemic Cholangiopathy (IC).
Sorry, not yet accepting patients
A prospective, open-label, single-arm, investigator-initiated study (SELIC) to evaluate the efficacy and safety of seladelpar in adult liver transplant recipients with Ischemic cholangiopathy (IC).

Our lead scientists for Ischemic Cholangiopathy research studies include Veeral Ajmera.

Last updated: December 12, 2025

Single-arm, Investigator-initiated Study (SELIC) to Evaluate the Efficacy and Safety of Seladelpar in Adult Liver Transplant Recipients With Ischemic Cholangiopathy (IC).